Bilcare Technologies - Preventing counterfeiting of pharmaceutical drugs with track and trace technology

Published on 18-May-2010

Validated on 07 Feb 2014

"The IBM-enabled pilot is the first step in Bilcare Technologies’ on-going journey to commercially launch a counterfeit detection and product serialization solution." - Manoj Arora, CIO, Bilcare

Customer:
Bilcare Technologies

Industry:
Life Sciences

Deployment country:
India

Solution:
C-Suite Framework, Smarter Planet

Smarter Planet:
Smart Products, Smarter Healthcare, Smarter Public Safety

Overview

Bilcare Limited is a global provider of innovative solutions for the pharmaceutical industry. The company provides a wide range of solutions, from research and clinical services to packaging materials and manufacturing.

Business need:
The World Health Organization (WHO) estimates that approximately ten percent of the worldwide drug supply is counterfeit, resulting in a major risk that can turn a potentially life-saving drug into a killer. In order to develop the first-of-its-kind non-clonable fingerprint authentication technology, Bilcare needed to work with a technology leader that could offer a comprehensive track-and-trace framework.

Solution:
Bilcare Technologies worked with IBM Global Business Services to develop a pilot solution based on the IBM Product Track-and-Trace Solution framework. The solution incorporates Electronic Product Code Information System (EPCIS)-compliant IBM InfoSphere Traceability Server software into the Bilcare non-clonable authentication technology.

Benefits:
Bilcare’s technology can now be seamlessly integrated into any supply chain system, providing real-time product authentication; The technology helps businesses in the pharmaceutical industry detect counterfeit goods, potentially saving millions of lives

Case Study

Bilcare Limited is a global provider of innovative solutions for the pharmaceutical industry. The company provides a wide range of solutions, from research and clinical services to packaging materials and manufacturing.

The Need
The World Health Organization (WHO) estimates that approximately ten percent of the worldwide drug supply is counterfeit, resulting in a major risk that can turn a potentially life-saving drug into a killer. In order to develop the first-of-its-kind non-clonable fingerprint authentication technology, Bilcare needed to work with a technology leader that could offer a comprehensive track-and-trace framework.

The Solution
Bilcare Technologies worked with IBM Global Business Services to develop a pilot solution based on the IBM Product Track-and-Trace Solution framework. The solution incorporates Electronic Product Code Information System (EPCIS)-compliant IBM InfoSphere Traceability Server software into the Bilcare non-clonable authentication technology.

What Makes it Smarter
- Bilcare’s technology can now be seamlessly integrated into any supply chain system, providing real-time product authentication
- The technology helps businesses in the pharmaceutical industry detect counterfeit goods, potentially saving millions of lives

For more information
Please contact your IBM sales representative or IBM Business Partner. Visit us at:
ibm.com/lifesciences

Products and services used

IBM products and services that were used in this case study.

Software:
WebSphere Portal, InfoSphere Traceability Server

Service:
IBM Global Business Services

Legal Information

© Copyright IBM Corporation 2010 IBM Corporation 1 New Orchard Road Armonk, NY 10504 U.S.A. Produced in the United States April 2010 All Rights Reserved IBM, the IBM logo, ibm.com, InfoSphere and WebSphere are trademarks of International Business Machines Corporation, registered in many jurisdictions worldwide. A current list of IBM trademarks is available on the Web at “Copyright and trademark information” at ibm.com/legal/copytrade.shtml Other company, product or service names may be trademarks or service marks of others. The information contained in this documentation is provided for informational purposes only. While efforts were made to verify the completeness and accuracy of the information contained in this documentation, it is provided “as is” without warranty of any kind, express or implied. In addition, this information is based on IBM’s current product plans and strategy, which are subject to change by IBM without notice. IBM shall not be responsible for any damages arising out of the use of, or otherwise related to, this documentation or any other documentation. Nothing contained in this documentation is intended to, nor shall have the effect of, creating any warranties or representations from IBM (or its suppliers or licensors), or altering the terms and conditions of the applicable license agreement governing the use of IBM software.